Zydus Lifesciences Limited (ZYDUSLIFE.BO)
INR 859.55
(2.64%)
INR 859.55
(2.64%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 | 71.79 Billion INR | 18.31% |
| 2023 | 60.68 Billion INR | -30.58% |
| 2022 | 87.41 Billion INR | -2.38% |
| 2021 | 89.55 Billion INR | -25.23% |
| 2020 | 119.76 Billion INR | 1.46% |
| 2019 | 118.03 Billion INR | 29.29% |
| 2018 | 91.29 Billion INR | 12.65% |
| 2017 | 81.04 Billion INR | 71.87% |
| 2016 | 47.15 Billion INR | 6.29% |
| 2015 | 44.36 Billion INR | 0.76% |
| 2014 | 44.03 Billion INR | 2.15% |
| 2013 | 43.1 Billion INR | 15.05% |
| 2012 | 37.46 Billion INR | 57.94% |
| 2011 | 23.72 Billion INR | 14.56% |
| 2010 | 20.7 Billion INR | -0.95% |
| 2009 | 20.9 Billion INR | 40.46% |
| 2008 | 14.88 Billion INR | 31.53% |
| 2007 | 11.31 Billion INR | 29.55% |
| 2006 | 8.73 Billion INR | 13.89% |
| 2005 | 7.66 Billion INR | -4.84% |
| 2004 | 8.05 Billion INR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 FY | 71.79 Billion INR | 18.31% |
| 2024 Q1 | - INR | -100.0% |
| 2024 Q4 | 71.79 Billion INR | 0.0% |
| 2024 Q3 | - INR | -100.0% |
| 2024 Q2 | 49.38 Billion INR | 0.0% |
| 2023 Q1 | - INR | -100.0% |
| 2023 Q3 | - INR | -100.0% |
| 2023 FY | 60.68 Billion INR | -30.58% |
| 2023 Q4 | 60.68 Billion INR | 0.0% |
| 2023 Q2 | 68.61 Billion INR | 0.0% |
| 2022 Q3 | - INR | -100.0% |
| 2022 Q1 | - INR | -100.0% |
| 2022 Q4 | 87.41 Billion INR | 0.0% |
| 2022 FY | 87.41 Billion INR | -2.38% |
| 2022 Q2 | 92.95 Billion INR | 0.0% |
| 2021 Q2 | 109.16 Billion INR | 0.0% |
| 2021 Q4 | 89.55 Billion INR | 0.0% |
| 2021 FY | 89.55 Billion INR | -25.23% |
| 2020 Q4 | 119.76 Billion INR | 0.0% |
| 2020 FY | 119.76 Billion INR | 1.46% |
| 2020 Q2 | 114.23 Billion INR | 0.0% |
| 2019 Q2 | 89.5 Billion INR | 0.0% |
| 2019 FY | 118.03 Billion INR | 29.29% |
| 2019 Q4 | 118.03 Billion INR | 0.0% |
| 2018 Q2 | 87.05 Billion INR | 0.0% |
| 2018 Q4 | 91.29 Billion INR | 0.0% |
| 2018 FY | 91.29 Billion INR | 12.65% |
| 2017 Q2 | 53.66 Billion INR | 0.0% |
| 2017 FY | 81.04 Billion INR | 71.87% |
| 2017 Q4 | 81.04 Billion INR | 0.0% |
| 2016 Q4 | 47.15 Billion INR | 0.0% |
| 2016 FY | 47.15 Billion INR | 6.29% |
| 2016 Q2 | 46.05 Billion INR | 0.0% |
| 2015 Q2 | 43.97 Billion INR | 0.0% |
| 2015 Q4 | 44.36 Billion INR | 0.0% |
| 2015 FY | 44.36 Billion INR | 0.76% |
| 2014 Q4 | 44.03 Billion INR | 0.0% |
| 2014 Q2 | 46.65 Billion INR | 0.0% |
| 2014 FY | 44.03 Billion INR | 2.15% |
| 2013 FY | 43.1 Billion INR | 15.05% |
| 2013 Q2 | 39.79 Billion INR | 0.0% |
| 2013 Q4 | 43.1 Billion INR | 0.0% |
| 2012 Q4 | 37.46 Billion INR | 0.0% |
| 2012 FY | 37.46 Billion INR | 57.94% |
| 2011 FY | 23.72 Billion INR | 14.56% |
| 2010 FY | 20.7 Billion INR | -0.95% |
| 2009 FY | 20.9 Billion INR | 40.46% |
| 2008 FY | 14.88 Billion INR | 31.53% |
| 2007 FY | 11.31 Billion INR | 29.55% |
| 2006 FY | 8.73 Billion INR | 13.89% |
| 2005 FY | 7.66 Billion INR | -4.84% |
| 2004 FY | 8.05 Billion INR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 16.27 Billion INR | -341.151% |
| Aurobindo Pharma Limited | 152.2 Billion INR | 52.833% |
| Glenmark Life Sciences Limited | 5.18 Billion INR | -1285.705% |
| Granules India Limited | 22.95 Billion INR | -212.759% |
| Indoco Remedies Limited | 10.34 Billion INR | -594.159% |
| Achyut Healthcare Limited | 2.01 Million INR | -3566318.281% |
| Ajanta Pharma Limited | 10.71 Billion INR | -570.308% |
| Alkem Laboratories Limited | 48.6 Billion INR | -47.705% |
| Alpa Laboratories Limited | 307.12 Million INR | -23275.727% |
| Brooks Laboratories Limited | 248.6 Million INR | -28778.404% |
| AstraZeneca Pharma India Limited | 3.66 Billion INR | -1860.936% |
| Bajaj HealthCare Limited | 4.86 Billion INR | -1374.875% |
| Bliss GVS Pharma Limited | 2.1 Billion INR | -3304.318% |
| Dr. Reddy's Laboratories Limited | 106.96 Billion INR | 32.885% |
| Eris Lifesciences Limited | 38.26 Billion INR | -87.603% |
| FDC Limited | 3.7 Billion INR | -1835.508% |
| Glenmark Pharmaceuticals Limited | 65.11 Billion INR | -10.261% |
| Gufic Biosciences Limited | 5.59 Billion INR | -1182.043% |
| Ind-Swift Laboratories Limited | 2.28 Billion INR | -3035.76% |
| Ipca Laboratories Limited | 33.74 Billion INR | -112.762% |
| Jagsonpal Pharmaceuticals Limited | 296.76 Million INR | -24091.94% |
| Krebs Biochemicals & Industries Limited | 2.97 Billion INR | -2314.058% |
| Lasa Supergenerics Limited | 541.92 Million INR | -13147.59% |
| Laurus Labs Limited | 42.71 Billion INR | -68.074% |
| Lupin Limited | 96.23 Billion INR | 25.401% |
| Mankind Pharma Limited | 23.87 Billion INR | -200.704% |
| Medicamen Biotech Limited | 940.36 Million INR | -7534.466% |
| Medico Remedies Limited | 438.24 Million INR | -16281.742% |
| Megasoft Limited | 1.85 Billion INR | -3774.067% |
| NATCO Pharma Limited | 10.53 Billion INR | -581.656% |
| Piramal Pharma Limited | 74 Billion INR | 2.99% |
| RPG Life Sciences Limited | 1.38 Billion INR | -5101.565% |
| Sigachi Industries Limited | 2.53 Billion INR | -2736.21% |
| Sun Pharmaceutical Industries Limited | 183.56 Billion INR | 60.891% |
| Suven Pharmaceuticals Limited | 2.03 Billion INR | -3429.2% |
| Syncom Formulations (India) Limited | 1.16 Billion INR | -6061.288% |
| Unichem Laboratories Limited | 8.06 Billion INR | -789.698% |
| Wanbury Limited | 3.15 Billion INR | -2175.126% |
| Windlas Biotech Limited | 1.76 Billion INR | -3972.843% |
| ZIM Laboratories Limited | 2.08 Billion INR | -3350.274% |
| Sun Pharma Advanced Research Company Limited | 3.89 Billion INR | -1744.178% |
| Divi's Laboratories Limited | 18.99 Billion INR | -278.052% |
| Hester Biosciences Limited | 3.59 Billion INR | -1897.151% |
| Procter & Gamble Health Limited | 2.56 Billion INR | -2703.061% |
| Amrutanjan Health Care Limited | 783.82 Million INR | -9059.199% |
| Bal Pharma Limited | 2.51 Billion INR | -2758.786% |
| Strides Pharma Science Limited | 37.68 Billion INR | -90.528% |
| Venus Remedies Limited | 1.39 Billion INR | -5054.509% |
| Aarti Pharmalabs Limited | 8.25 Billion INR | -770.132% |
| Nectar Lifesciences Limited | 11.21 Billion INR | -539.967% |
| Shilpa Medicare Limited | 12.93 Billion INR | -455.13% |
| Aarti Drugs Limited | 11.5 Billion INR | -524.061% |
| IOL Chemicals and Pharmaceuticals Limited | 6.32 Billion INR | -1034.352% |
| Suven Life Sciences Limited | 148.62 Million INR | -48205.421% |
| Ind-Swift Limited | 13.45 Billion INR | -433.652% |
| Valiant Laboratories Limited | 1.05 Billion INR | -6683.973% |
| J. B. Chemicals & Pharmaceuticals Limited | 10.7 Billion INR | -570.452% |
| Solara Active Pharma Sciences Limited | 14.14 Billion INR | -407.586% |
| Themis Medicare Limited | 1.88 Billion INR | -3703.528% |
| Hikal Limited | 12.99 Billion INR | -452.463% |
| Torrent Pharmaceuticals Limited | 82.05 Billion INR | 12.502% |
| Sequent Scientific Limited | 8.27 Billion INR | -767.656% |
| Novartis India Limited | 1.8 Billion INR | -3886.009% |
| Wockhardt Limited | 39.87 Billion INR | -80.065% |
| Jubilant Pharmova Limited | 61.27 Billion INR | -17.166% |
| Biofil Chemicals and Pharmaceuticals Limited | 288.79 Million INR | -24758.812% |
| Neuland Laboratories Limited | 5.49 Billion INR | -1205.65% |
| Morepen Laboratories Limited | 4.45 Billion INR | -1509.762% |
| Kilitch Drugs (India) Limited | 643.88 Million INR | -11049.852% |
| Mangalam Drugs & Organics Limited | 1.97 Billion INR | -3532.627% |